Perrigo (PRGO) Q1 2026 earnings review
Core Volumes Collapse as 'Transition Year' Begins with a $330M Write-Down
Perrigo’s Q1 2026 results confirm management's warning that this will be a painful transition year. Top-line results were dismal: Core organic net sales plummeted 11.0%, driven by a weak cough/cold season and aggressive retailer destocking. A massive $330.8M goodwill impairment wiped out reported earnings to $(2.81) per share. Even excluding the write-down, Adjusted EPS fell 28% to $0.43 due to severe margin compression from manufacturing under-absorption. The successful divestiture of the Dermacosmetics unit for €306M provides much-needed balance sheet relief, but the steep underlying volume declines mean Perrigo’s reiterated FY26 guidance rests entirely on a speculative second-half recovery.
🐂 Bull Case
The Dermacosmetics divestiture closed post-quarter, yielding €306M in upfront cash. This directly supports the urgent need to pay down debt and reduce the company's elevated 4.0x net leverage ratio.
The Specialty Care segment bucked the negative trend, growing revenues by 4.0% and operating income by 31.4%, driven by strong momentum in Women's Health brands like Opill and ellaOne.
🐻 Bear Case
Core organic volume/mix collapsed 11.0%. While management blames weather and destocking, the magnitude of the drop suggests broader category weakness and structural headwinds.
Prior-year volume declines are now hitting the P&L via manufacturing under-absorption. This dynamic compressed Core Adjusted Operating Margin by 110 bps and will drag on earnings for the rest of the year.
⚖️ Verdict: 🔴
Bearish. While the Dermacosmetics sale improves the balance sheet, the underlying operations are deteriorating rapidly. An 11% drop in core organic volume and a reliance on a steep H2 recovery make the reiterated guidance highly precarious.
Key Themes
Core Volume/Mix Collapse Contradicts Share Gain Narrative
Management touted a 100 bps volume share gain in U.S. Store Brand OTC. However, Core organic volume/mix plunged a staggering 11.0%. This severe contradiction implies that either the overall market is shrinking much faster than Perrigo can gain share, or the company is bleeding volume in unmentioned categories. Management quantified headwinds from destocking (-3.0%) and a weak cold season (-3.5%), but that still leaves a significant unexplained 4.5% gap in volume destruction.
$330M Goodwill Impairment Highlights Past Missteps
A massive $330.8M non-cash goodwill impairment charge crashed reported operating margins to a dismal (38.4)%. This charge realizes the warning management gave during the Q4 2025 call, explicitly highlighting the severe, long-term underperformance of historical acquisitions relative to their purchase prices.
Specialty Care and Women's Health Buck the Trend
Amidst the widespread top-line carnage, Specialty Care was the lone bright spot. Segment net sales grew 4.0% to $207M, and operating income surged 31.4% to $55M. The growth was spearheaded by the Women’s Health portfolio—specifically the continued market traction of Opill and ellaOne. This proves that focused, category-led innovation can yield high-margin growth even in a broadly soft macro environment.
Manufacturing Under-Absorption Crushes Margins
Core adjusted operating margin dropped 110 bps to 12.8%. The primary culprit was gross margin flow-through from prior-year manufacturing volume headwinds. Because Perrigo produced less inventory last year, those unabsorbed fixed plant costs are now hitting the P&L. Management disclosed this specific dynamic carries a $0.60 full-year EPS impact, with $0.26 realized in Q1 alone. If sales volumes don't rapidly recover, these fixed costs will continue to suffocate profitability.
Portfolio Simplification Yields Immediate Cash
The 'Streamline' pillar of the Three-S plan delivered a major win. After the quarter ended, Perrigo closed the sale of its Dermacosmetics business for up to €332.6M (€305.6M upfront cash). Management explicitly stated these proceeds will be used to support debt reduction, which is critical given the company's stated goal to aggressively lower its leverage ratio.
Tariff Clawbacks Provide Temporary Margin Relief
On the macro front, Perrigo successfully recorded a net recognition of approximately $21M from a recovery of previously paid tariffs. This one-time cash and margin benefit provided a vital offset to the quarter's severe gross margin pressures, showcasing the legal and supply chain team's ability to mitigate global trade friction.
Other KPIs
Down a staggering 39.3% YoY. The collapse was driven by the 11.5% drop in net sales, lower plant overhead absorption, and unfavorable product mix. The decline in high-margin Upper Respiratory and Pain & Sleep products severely damaged segment profitability.
Cash generation deteriorated further from the $64.5M outflow seen in Q1 2025. Management attributed this to lower earnings and higher working capital requirements. While Q1 is historically a softer cash flow quarter, the magnitude of the outflow puts pressure on the remainder of the year to fund the dividend and operations.
Guidance
Stable. The company maintained its guidance range. However, having generated only $0.43 in Q1, the guidance implies a massive, high-risk acceleration in the second half of the year, driven heavily by expected cost savings and a normalization of retailer inventory.
Accelerating. Reversing from the disastrous -11.0% print in Q1, management expects sales to significantly improve over the next three quarters. This relies on the assumption that the 3.0% destocking headwind is purely transitory.
Accelerating. Improving from the 12.8% printed in Q1. The bridge to this margin expansion requires the cessation of manufacturing under-absorption penalties and the realization of planned savings from the Operational Enhancement Program.
Key Questions
Visibility into Destocking
You cited a 3.0% net sales headwind from retailer inventory destocking. What specific point-of-sale data or retailer conversations give you confidence that this destocking phase will end in Q2 rather than extending into the second half of the year?
Bridging the Volume Gap
Core organic volume/mix declined 11.0%. Even adjusting for the 6.5% combined headwind from cold season and destocking, volumes are still down mid-single digits despite your stated 100 bps share gain in U.S. Store Brands. Where exactly is the rest of the volume bleeding from?
Infant Formula Strategic Review
Infant Formula sales grew 2.1% this quarter. What is the current timeline and status of the strategic review for this business, and has the recent performance shifted your view on a potential divestiture?
Opill Investment Strategy
You noted planned lower investment levels for Opill in Q1. Given the brand's success and its role as a primary growth driver, why are you reducing promotional spend, and how does this impact the long-term plan to build a broader Women's Health platform?